University of Connecticut

Bristol-myers Squibb Compnay

Glaxosmithkline Intellectual Property Development Limited

Praecis Pharmaceuticals, Inc.

Daimed

Daiamed, Inc.

Hongfeng Deng

Alexandros Makriyannis

Jian Lin

Lei Jin

Thomas D Bannister

Michael Rynkiewicz

Ghotas Evindar

Sing-Yuen Sit

Kerry Leigh Spear

Amy Ripka

Martha Alicia De La Rosa

Wieslaw Mieczyslaw Kazmierski

Manuel A Navia

Cassandra Celatka

Tsvetelina Ivanova Lazarova

Sherin Salaheldin Abdel-Meguid

Vicente Samano

Roger Xie

Harold V Meyers

David T Weaver

Zihong Guo

Nizal Chandrakumar

Robert Edward Babine

Kai Xie

Yoshiaki Washio

Gang Yao

John Franklin Miller

Scott T Moe

Hongfang Yang

Pamela Nagafuji

James E Stickler

Scott R Magee

Pramod Pandey

Zihong Gho

Aaron Coffin

Sylvie Bernier

Bing Xia

Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases. 

Modulators of indoleamine 2,3-dioxygenase

Disclosed are cannabimimetic aminoalkylindole compounds and methods for their manufacture. The disclosed compounds are surprisingly potent and selective cannabinoids. The disclosed compounds may include radioactive atoms. Also disclosed are methods of using the disclosed compounds, including use of the disclosed compounds to stimulate a cannabinoid receptor, to provide a physiological effect in an animal or individual, to treat a condition in an animal or individual and for use in radioimaging.

Receptor selective cannabimimetic aminoalkylindoles

The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or S1P receptors.

Sphingosine-1-phosphate (SIP) receptor agonists

Compounds are provided which have the structure Wherein A, B, C, D, m, Y, Ra, Rc, Rd, and Rd' are as described herein, and which are useful as inhibitors of tryptase, thrombin, trypsin, Factor Xa, Factor VIIa, Factor XIa, and urokinase-type plasminogen activator and may be employed in preventing and/or treating asthma, chronic asthma, allergic rhinitis, and thrombotic disorders.

Substituted azetidinones

Disclosed are heterocyclic compounds and methods for their manufacture. The disclosed compounds are surprisingly potent and selective cannabinoids. Also disclosed are methods of using the disclosed compounds, including use of the disclosed compounds to stimulate a cannabinoid receptor, to provide a physiological effect in an animal or individual and to treat a condition in an animal or individual.

Cannabimimetic ligands

Cannabimimetic indole derivatives are presented which have preferentially high affinities for one of the cannabinoid CB1 or CB2 receptor sites. The improved receptor affinity makes these analogs therapeutically useful as medications in individuals and animals.

Cannabimimetic indole derivatives

The present invention provides compounds that inhibit Factor XIa and methods of preventing or treating undesired thrombosis by administering a compound of the invention to a mammal. The invention also provides three-dimensional structures of Factor XIa and methods for designing or selecting additional Factor XIa inhibitors using these structures.

Compounds and methods for treatment of thrombosis

Disclosed are cannabimimetic aminoalkylindole compounds and methos for their manufacture. The disclosed compounds are surprisingly potent and selective cannabinoinds. Also disclosed are methods of using the disclosed compounds, including use of the disclosed compounds to stimulate a cannabinoid receptor, to provide a physiological effect in an animal or individual and to treat a condition in an animal or individual.

The present invention relates to novel oxime carbamyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase. These pharmaceutical compositions are useful for the treatment of conditions which can be effected by inhibiting fatty acid amide hydrolase including, but not limited to, neuropathic pain, emesis, anxiety, altering feeding behaviors, movement disorders, glaucoma, brain injury, and cardiovascular disease.

(Oxime)carbamoyl fatty acid amide hydrolase inhibitors

Novel cannabimimetic indole derivatives are presented which have preferential high affinities for one of the cannabinoid CB1 CB2 receptor sites. The improved receptor affinity makes these analogs therapeutically useful as medications in individuals and animals for treatment of pain, glaucoma, epilepsy, nausea associated with chemotherapy.

Growing community of inventors

Acton, MA, United States of America

Hongfeng Deng